Efficacy of Tixagevimab-Cilgavimab as Immunoprophylaxis in Patients With Hematologic Cancer.

Marco Salvini,Paolo Antonio Grossi, Alessandro Cacioppo,Michele Merli,Giacomo Pellegrini,Marco Brociner,Francesco Passamonti

JAMA oncology（2024）

引用 0|浏览3

暂无评分

摘要

This cohort study compares outcomes for patients with hematologic malignant tumors who prophylactically received tixagevimab-cilgavimab against SARS-CoV-2 with those who did not.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要